Holidays may affect clinic and pharmacy hours. Please call before visiting.
Samir Mukundray Dalia, MD
Mercy Clinic
Samir Mukundray Dalia, MD
Specialty
- Oncology
- Hematology
Select a Location
To schedule an in-person or video visit (available only through certain locations).
Select a Visit Type
To ensure the highest quality patient care, please select the most appropriate visit type, as length of visits vary. If you do not see your visit type, please call.
No visits are currently available.
Select a Time
Please select your preferred time slot for your appointment.
Location and Contact Information
About Samir Mukundray Dalia, MD
Education
Medical School
- Northeast Ohio University
Fellowships
- University of South Florida-Hematology/Oncology
Residency
- Alpert Medical School - Brown University-Internal Medicine
Specialty
Board Certifications
- American Board of Internal Medicine
- American Board of Internal Medicine (Medical Oncology)
- American Board of Internal Medicine(Hematology)
Affiliations
- Mercy Hospital Joplin
Languages
- English
Publications
- Dalia S, Suleiman Y, Croy DW, Sokol L. Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. "Cancer Control."-2015 Jul;22(3):360-5.
- Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. "Int J Hematol"-2014 Dec; 100(6):567-74.
- Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic Characteristics and Outcomes of Histiocytic and Dendritic Cell Neoplasms: The Moffitt Cancer Center Experience over the last twenty five years . "Cancers."-2014 Nov 14;6(4):2275-2295.
- Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. "Leukemia Research"-2014 Oct;38(10):1165-72.
- Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high dose methotrexate in the initial treatment of Primary Central Nervous System Lymphoma? "Leukemia and Lymphoma."-2014 Jul 17:1-3.
- Reagan JL, Ingham RR, Dalia S, Butera JN, Sweeney JD. Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing. "Thrombosis Research"-2014 Jul; 134(1):90-2.
- Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee J, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. International Journal of Hematology.-2014 April 99(4);450-6.
- Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin Disease in Chronic Lymphocytic Leukemia coexisting with Epstein Barr viremia. "Leukemia and Lymphoma."-2014 Mar 18 epub ahead of print.
- Dalia S, Dunker K, Sokol L, Mhaskar R. Hepatitis B seropositivity and risk of developing multiple myeloma or Hodgkin lymphoma: A meta-analysis of observational studies. "Leuk Res."-2015 Sep 9 E pub ahead of print
- Chavez JC, Dalia S, Sandoval-Sus J, et al. Second Myeloid Malignancies in a Large Cohort of Patients with Chronic Lymphocytic Leukemia: A Single Institution Experience. "Clin Lymphoma Myeloma Leuk."-2015 Jun; 15 Suppl:S14-8
- Sandoval-Sus, JD, Chavez J, Dalia S. A new therapeutic era in GCB and ABC Diffuse large B-cell lymphoma molecular subtypes: a cell of origin driven review. "Curr Cancer Drug Targets."-2015 Oct 29 Epub ahead of print
- Castillo J, Bower, m, Novak U, Bruhlmann J, Furrer H, Tanaka P, Besson C, Montoto S, Cwynarski K, Abramson J, Dalia S et al. Prognostic factors for advanced stage HIV-associated classical Hodgkin lymphoma treated with ABVD and combined antiretroviral therapy: A multi-institutional retrospective study. "Cancer."-2015 Feb 1;121(3):423-31.
- Chavez J, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke F. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. "Leukemia Research."-2014 Apr 28. Pii: S0145-2126(14)00117-9 epub ahead of print.
- Castillo JJ, Ingham R, Reagan J, Furman M, Dalia S, Mitri J. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: A meta-analysis of observation studies. "Clinical Lymphoma, Myeloma, and Leukemia."-2013 April 14 (2)122-30.
Looking for more options?
Find the Mercy provider who's right for you.
View all Oncology providers.
Looking for more options?
Find the Mercy provider who's right for you.
View all Oncology providers.
Insurance Accepted
This listing is provided as a guide only. Please verify with your insurance provider.Mercy accepts most plans under this insurance provider. Please verify with your insurance provider before scheduling.
Mercy typically accepts the following plans:
- {{ plan }}
Plan not found. Call office number to verify.
Mercy accepts most plans under this insurance provider. Please verify with your insurance provider before scheduling.
Mercy typically accepts the following plans:
- {{ plan }}
Type in your health insurance provider above or select from the list to see accepted plans by provider.
Comments